Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04093362
Title Futibatinib Vs Gemcitabine-Cisplatin Chemotherapy as 1st-Line Treatment of Patients With Advanced Cholangiocarcinoma (CCA) Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Taiho Oncology, Inc.
Indications

intrahepatic cholangiocarcinoma

Therapies

Futibatinib

Cisplatin + Gemcitabine

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | BEL

Additional content available in CKB BOOST